Pentax, Motus GI & more — 4 GI company key notes

Here are four updates on GI companies from the past week:

Theravance Biopharma Ireland and Janssen Biotech entered into a co-development and commercialization agreement over TD-1473, an inflammatory intestinal disease inhibitor.

Motus GI will sell 4.25 million shares of its common stock at $6 per share as it attempts to raise $25.5 million through a U.S.-based initial public offering

The FDA and Pentax announced a voluntary recall of all ED-3490TK video duodenoscopes to replace a series of parts and update the operations manual.

Ferring Pharmaceuticals' low-volume bowel preparation Clenpiq is now available in the U.S. via prescription.

More articles on gastroenterology:
UroLife designates Midtown Urology Associates a UroLife Center of Excellence: 3 insights
The definition of 'outpatient' ACDF and lumbar discectomy procedures can be misleading: 5 insights
Senate report: 5 opioid manufacturers paid $9M to 14 patient advocacy groups — 8 insights

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers